MedPath

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Phase 3
Completed
Conditions
Bipolar I Disorder
Interventions
Drug: Placebo
First Posted Date
2004-10-19
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
650
Registration Number
NCT00094432
Locations
🇺🇸

Local Institution, Charleston, West Virginia, United States

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Phase 3
Completed
Conditions
Ulcerative Colitis
First Posted Date
2004-09-28
Last Posted Date
2007-06-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
1725
Registration Number
NCT00092508
Locations
🇺🇸

Sooner Clinical Research, Oklahoma City, Oklahoma, United States

🇺🇸

McGuire DVAMC, Richmond, Virginia, United States

🇺🇸

Center for Digestive and Liver Diseases, Mexico, Missouri, United States

and more 23 locations

Study of Aripiprazole in Subjects With Alcoholism

Phase 4
Completed
Conditions
Alcoholism
Interventions
Drug: Placebo
First Posted Date
2004-05-04
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
400
Registration Number
NCT00082199
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2004-03-30
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
370
Registration Number
NCT00080327
Locations
🇺🇸

Bristol-Meyers Squibb Call Center, Wallingford, Connecticut, United States

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
First Posted Date
2004-03-30
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
400
Registration Number
NCT00080314
Locations
🇺🇸

Local Institution, Bellevue, Washington, United States

🇺🇸

Local Insstitution, Honolulu, Hawaii, United States

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Phase 3
Completed
Conditions
Hyponatremias
Water Intoxication
Inappropriate ADH Syndrome
Water-Electrolyte Imbalances
First Posted Date
2003-11-11
Last Posted Date
2007-01-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
240
Registration Number
NCT00072683
Locations
🇺🇸

VA Greater Los Angeles Health Care Ctr, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Mercury Street Medical, Butte, Montana, United States

and more 19 locations

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Phase 3
Completed
Conditions
Congestive Heart Failure
First Posted Date
2003-10-21
Last Posted Date
2012-05-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
3600
Registration Number
NCT00071331
Locations
🇳🇴

Hjertemed.avd. Akershus Universitetssykenhus, Nordbyhagen, Norway

🇳🇴

Diakonhjemmets sykehus Oslo, Oslo, Norway

🇺🇸

The Heart and Vascular Institute of Florida, St. Petersburg, Florida, United States

and more 352 locations

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
First Posted Date
2003-07-10
Last Posted Date
2012-05-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
375
Registration Number
NCT00064454
Locations
🇺🇸

Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States

🇺🇸

Affiliates in Gastroeneterology, Florham Park, New Jersey, United States

🇺🇸

Gastrointestial Associates, PA, Jackson, Mississippi, United States

and more 25 locations

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
First Posted Date
2003-07-10
Last Posted Date
2012-05-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
375
Registration Number
NCT00064441
Locations
🇺🇸

Akron Gastroenterology Associates, Inc., Akron, Ohio, United States

🇺🇸

Lovelace Scientific Resources Florida, Miami, Florida, United States

🇺🇸

Miami Research Associates, Miami, Florida, United States

and more 20 locations

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar I Disorder
First Posted Date
2002-10-01
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00046384
Locations
🇦🇷

Local Institution, Mendoza, Argentina

© Copyright 2025. All Rights Reserved by MedPath